Compositions comprising β-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease
US10172907B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Oct 5, 2011 |
| Grant date | Jan 8, 2019 |
| Priority date | — |
| Expiry date | Mar 22, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4703
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of β-arrestin 1(βarr1) by the Angiotensin II (AngII) type 1 receptor (AT1R) mediates AngII-induced aldosterone production, β-arrestin 1(βarr1) is a therapeutic target for heart disease. The invention provides a βarr1 protein fragment comprising the C-terminus of βarr1 (βarr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of β-arrestin 1(βarr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of βarr1 activity and aldosterone production.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.